Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer

Bharali D. J., Yalcin M., Davis P. J., Mousa S. A.

NANOMEDICINE, cilt.8, sa.12, ss.1943-1954, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8 Sayı: 12
  • Basım Tarihi: 2013
  • Doi Numarası: 10.2217/nnm.12.200
  • Dergi Adı: NANOMEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1943-1954
  • Anahtar Kelimeler: angiogenesis, breast cancer, chick chorioallantoic membrane, MCF7 breast cancer cell, nanoparticle, tetrac, thyroid hormone, CELL-SURFACE RECEPTOR, THYROID-HORMONE, GROWTH-FACTOR, BIODEGRADABLE NANOPARTICLES, QUANTUM DOTS, IN-VITRO, DELIVERY, CHITOSAN, MICROPARTICLES, CARCINOMA
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Aim: The aim was to evaluate tetraiodothyroacetic acid (tetrac), a thyroid hormone analog of l-thyroxin, conjugated to poly(lactic-co-glycolic acid) nanoparticles (T-PLGA-NPs) both in vitro and in vivo for the treatment of drug-resistant breast cancer. Materials & methods: The uptake of tetrac and T-PLGA-NPs in doxorubicin-resistant MCF7 (MCF7-Dx) cells was evaluated using confocal microscopy. Cell proliferation assays and a chick chorioallantoic membrane model of FGF2-induced angiogenesis were used to evaluate the anticancer effects of T-PLGA-NPs. In vivo efficacy was examined in a MCF7-Dx orthotopic tumor BALBc nude mouse model. Results: T-PLGA-NPs were restricted from entering into the cell nucleus, and T-PLGA-NPs inhibited angiogenesis by 100% compared with 60% by free tetrac. T-PLGA-NPs enhanced inhibition of tumor-cell proliferation at a low-dose equivalent of free tetrac. In vivo treatment with either tetrac or T-PLGA-NPs resulted in a three- to five-fold inhibition of tumor weight. Conclusion: T-PLGA-NPs have high potential as anticancer agents, with possible applications in the treatment of drug-resistant cancer. Original submitted 2 May 2012; Revised submitted 21 November 2012